Atalanta Therapeutics Secures $75 Million in Series B Funding
Atalanta Therapeutics is stepping into the future of medicine with its groundbreaking approach to RNA interference (RNAi), specifically designed to tackle serious neurological diseases. In an exciting development, the company has secured a substantial $75 million in Series B funding, enabling it to advance its innovative therapies aimed at treating epilepsy and Huntington's disease.
Funding Details and Investors
This Series B financing is a pivotal moment for Atalanta, as it prepares to commence Phase 1 clinical trials for its RNAi therapies aimed at KCNT1-related epilepsy and Huntington’s disease. The funding round is spearheaded by EQT Life Sciences, which operates its LSP Dementia Fund, along with notable contributions from Sanofi Ventures, RiverVest Venture Partners, abrdn, Inc., Mirae Asset Financial Group, and F-Prime Capital.
Innovative Therapeutic Approach
Atalanta’s pioneering di-siRNA platform uniquely positions them to deploy RNAi therapeutics throughout the brain and spinal cord, effectively revolutionizing the way neurological conditions can be treated. RNA, as a molecular carrier of genetic information, is crucial for protein synthesis. By utilizing RNAi, Atalanta can potentially silence harmful genes responsible for neurological diseases, ushering in a new era of treatment possibilities.
Statements from Leadership
Alicia Secor, M.B.A., the President and CEO of Atalanta, expressed her enthusiasm regarding the support from EQT Life Sciences and the other investors. She stated, "This Series B funding will propel our efforts toward developing two vital programs for neurological diseases that currently lack disease-modifying therapies. Our team is working diligently to advance these therapies toward IND submissions to initiate our Phase 1 trials and deliver impactful solutions to patients in need."
Promise of di-siRNA Technology
Dr. Arno de Wilde, M.D., Ph.D., M.B.A., Managing Director at EQT Life Sciences, commented on the di-siRNA technology’s potential, highlighting its ability to durably silence disease-promoting genes across challenging regions within the brain and spinal cord. This innovative technology opens new pathways for treating devastating neurological conditions, creating hope for patients who have limited options.
Impacts of Series B Financing
The latest round of funding not only brings Atalanta's total capital raised from financing and partnerships to an impressive $240 million but also signifies the growing interest in RNAi therapies among leading investors. This financial backing positions Atalanta to push forward with its cutting-edge technology and move closer to clinical realities.
Looking Ahead
With the successful completion of this funding round, Atalanta Therapeutics is poised to continue its forward momentum. The company is now on track to start clinical trials that could provide breakthrough treatments for conditions that are currently challenging to manage. The collaboration among top-tier investors reflects broad confidence in Atalanta's vision and its commitment to advancing healthcare.
Frequently Asked Questions
What does Atalanta Therapeutics specialize in?
Atalanta Therapeutics focuses on RNA interference (RNAi) technologies aimed at treating neurological diseases like epilepsy and Huntington's disease.
How much funding did Atalanta Therapeutics secure in their Series B round?
Atalanta Therapeutics secured $75 million in its Series B funding round.
Who led the funding round for Atalanta?
The funding round was led by EQT Life Sciences in collaboration with other significant investors.
What is the purpose of the funding received by Atalanta?
The funding will support Phase 1 clinical trials for Atalanta’s RNAi therapies targeting KCNT1-related epilepsy and Huntington's disease.
What impact does the new funding have on Atalanta’s total capital?
This Series B financing raises Atalanta's total capital raised to date to approximately $240 million.
